The 2024 report highlights the growth and evolution of patents, trademarks, and industrial designs across key global economies, with particular attention to emerging markets and innovation hubs ...
As the FTC continues to crack down on pharmaceutical manufacturers’ allegedly improper listing of patents in the FDA Orange ...
Wolfe Research argues that despite a near-term impact, large-cap U.S. pharma stocks are largely immune from the anti-chronic ...
Liquidia's collaboration on L606 boosts long-term growth potential. Find out why LQDA stock’s valuation and upcoming launches ...
As Merck prepares for its blockbuster immunotherapy Keytruda to face generic competition, it’s investing in a new cancer drug ...
Which healthcare stock can dividend investors safely buy? Let's consider two excellent options: AbbVie (NYSE: ABBV) and Amgen (NASDAQ: AMGN).
Merck's undervalued stock presents growth opportunities with Keytruda and promising pipeline drugs, making it a Buy despite ...
Tharimmune (THAR) announced that the European Patent Office intends to grant the Company a patent covering biodegradable polymeric ...
A brief filed with the U.S. Supreme Court yesterday urged the Justices to deny a petition to the Court contending the U.S.
Sandoz Inc.’s proposed generic version of Inlyta infringes a patent for the kidney-cancer chemotherapy treatment, Pfizer Inc.
As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...
A slow launch for Alzheimer's medicine Leqembi, a lackluster pipeline and a challenging drug launch environment are just a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback